stockrowDexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) Return on invested capital
DexCom, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 39.0%, up 10.3 percentage points from fiscal 2025 (28.7%). Over the past ten years it has ranged from −40.4% (fiscal 2018) to 49.3% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −5.27% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 28.7% | (20.67) |
| FY2024 | 49.3% | 28.33 |
| FY2023 | 21.0% | 6.14 |
| FY2022 | 14.9% | 2.21 |
| FY2021 | 12.7% | (10.66) |
| FY2020 | 23.3% | 2.28 |
| FY2019 | 21.0% | 61.46 |
| FY2018 | −40.4% | (27.04) |
| FY2017 | −13.4% | 10.65 |
| FY2016 | −24.0% | 8.91 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| DXCM DexCom, Inc. | 39.0% |
| GEHC GE HealthCare Technologies Inc. compare | 8.86% |
| STE STERIS plc compare | 8.47% |
| EW Edwards Lifesciences Corporation compare | 7.79% |
| BSX Boston Scientific Corporation compare | 6.60% |
| PHG Koninklijke Philips N.V. compare | 6.15% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.66% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| GKOS Glaukos Corporation compare | −24.6% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement